TEVA Teva- Pharmaceutical Industries Ltd. - ADR

$TEVA again, whoever has been watching this thing move for years + has to be mind boggled by daily price movement. It’s insane to me how it’s acting. Very strange.

$TEVA FDA approved Weltruza on Friday, the first once-monthly subcutaneous olanzapine for schizophrenia. Teva expects US launch in the coming weeks. Compare it with the only other long-acting olanzapine, Zyprexa Relprevv: that one is intramuscular, needs 3 hours of post-injection observation in a certified facility under a REMS program, and patients can't drive home after. Weltruza drops all of that, no loading doses or oral supplementation either. Second US approval from the MedinCell SteadyTeq platform after Uzedy (risperidone, 2023). Shares hit fresh 52-week highs Friday.

$TEVA — Teva's stock shows upward momentum driven by FDA approval for schizophrenia treatment, alongside mixed financial performance. Recent analyses covered Teva Pharmaceutical Industries Limited (TEVA), noting its stock's upward momentum with positive short-term and long-term trends indicated by moving averages and RSI. The company's financial performance showed a slight year-over-year revenue decrease and a quarterly net loss, contrasting with a full-year net income in 2025. A key catalyst discussed was the FDA approval for a monthly schizophrenia shot, contributing to a year-to-date stock surge. On the upside: Stock trading above 50-day and 200-day SMAs, indicating positive medium and long-term trends. Positive short-term momentum indicated by 7-day, 30-day, and 91-day price changes. Positive MACD indicating bullish momentum. On the risk side: Quarterly revenue showed a year-over-year decrease of 0.8%. Reported a net loss of $576 million for the latest reported quarter.

$TEVA $BTAI …”as an acute, as-needed tool for agitation episodes in schizophrenia or bipolar disorder — distinct from maintenance therapies like long-acting injectables. “ At home use FDA approval pending early Nov.

$TEVA not your grandads Teva anymore. Volatility is crazy. If you’re new, it used to move Pfizer esc or move like it had a 6 trillion share float lol. This movement still boggles my mind.

$TEVA movement been wild since debut on nyse. 6 years watching this stock and its moving like it has no float. Very insane and interesting to say the least.

$TEVA looking good in the neighborhood! Should be a productive next few months, and beyond

$TEVA Teva Pharmaceutical Industries Ltd. (NYSE: TEVA): One of the largest generic manufacturers globally, producing oral formulations across all four classes (ciprofloxacin, levofloxacin, moxifloxacin, doxycycline).

$TEVA update: besides the $35M QVAR fund, Teva agreed to pull QVAR patents from the FDA Orange Book, which could help generic inhalers reach market. The suit alleges Teva stalled them. Claims closed; no payout date yet. Open Class Actions.

In the black at Teva Pharmaceutical Industries. $706M over the past 12 months, after losing $158M the year before. Scores a 16, top 100 of 3,283 stocks. $TEVA

$TEVA The harder part is still ahead... what are you takling about boy???? I got more than 500 p out of my money .... waiting for more than a ..

$TEVA $38.88 bid Holding long position at profit BRIEF:Teva (TEVA) said the FDA approved DEGEVMA (denosumab-adet) as a biosimilar to Amgen's (AMGN) Xgeva for all reference-product indications. Approved uses include preventing bone complications in adults with advanced cancer that has spread to bone, treating giant cell tumor of bone, and treating hypercalcemia of malignancy. Teva said DEGEVMA is its second FDA-approved biosimilar of 2026 and, with March-approved PONLIMSI, gives it a U.S. denosumab biosimilar portfolio spanning Xgeva and Prolia indications. The company expects to launch both DEGEVMA and PONLIMSI in the U.S. in the coming months.

$TEVA I am thinking to double down my holding now as this stock is going to go to $45 to $48 for the long term valued trading investment.

$TEVA This stock has been upgraded to the target price of $45. Stop trading and hold strong.

$TEVA Teva reducing debt by around $ 1.5 billion per year over the last 4 years .. Teva having a long + short term debt if $ 16.6/16.9 billion. Short term around $ 4.5 billion ... and at cash and cash equvialent position of $ 3.66 billion. DudeRooster is a shmok...

$TEVA Going in a good direction That will bring value For the share holders Sooner or later Probably sooner💪

$TEVA Sold my DKNG added more averaging up from 7.22 which has treated me well from 2017

$TEVA $39.50 Holding long position at $4.99 https://stocktwits.com/G101SPM/message/664258337 BRIEF: Teva (TEVA) initiated with an Outperform at Oppenheimer, tgt $50

$TEVA closed at a 52-week high on 2.8x its usual volume on Friday. The stock scores a 22 at the moment, Exceptional, and it's #2 of 305 in its industry.

$TEVA SST 3–5 Day Trading Strategy Preferred setup BULLISH WATCH BREAKOUT BUY Trade parameter Price Preferred pullback entry $40.20–40.80 Breakout entry Above $42.05 Stop loss $39.20 Target 1 $43.50 Target 2 $45.00 Extended target $46.50 Conditions for a strong BUY - Price holds above $40.20. - Breakout above $42.01. - Volume increases to at least 1.5× its recent consolidated average. - RSI remains above 50. - 1H chart confirms higher highs and higher lows. - Price maintains its position above the short-term EMA20.